文献速递骨软组织肉瘤与黑色素瘤

KEYNOTE-006 III期研究七年随访:帕博利珠单抗对比伊匹木单抗治疗晚期黑色素瘤

Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma.
PubMed 文献 · J Clin Oncol · 2023-06-22

KEYNOTE-006 III期研究七年随访显示,帕博利珠单抗对比伊匹木单抗在晚期黑色素瘤中持续延长总生存:中位总生存32.7个月对比15.9个月(HR 0.70,95%CI 0.58-0.83),7年总生存率37.8%对比25.3%。

要点

  • 中位总生存帕博利珠单抗32.7个月对比伊匹木单抗15.9个月(HR 0.70,95%CI 0.58-0.83)。
  • 7年总生存率帕博利珠单抗37.8%对比伊匹木单抗25.3%。
  • 完成≥94周帕博利珠单抗治疗者5年总生存率92.9%,5年改良无进展生存率70.1%。

核心结论

  • 帕博利珠单抗在晚期黑色素瘤中提供长期生存获益。

研究设计与样本

  • III期KEYNOTE-006研究七年随访更新,数据截止2021年4月19日,中位随访85.3个月(范围0.03-90.8个月)。

主要发现

  • 中位总生存帕博利珠单抗32.7个月对比伊匹木单抗15.9个月(HR 0.70,95%CI 0.58-0.83)。
  • 7年总生存率帕博利珠单抗37.8%对比伊匹木单抗25.3%。
  • 中位改良无进展生存帕博利珠单抗9.4个月对比伊匹木单抗3.8个月;7年改良无进展生存率23.8%对比13.3%。
  • 完成≥94周帕博利珠单抗治疗者5年总生存率92.9%,5年改良无进展生存率70.1%。
  • 第二疗程帕博利珠单抗(n=16)客观缓解率56%(95%CI 30-80),2年改良无进展生存率62.5%。

关键数值与推荐

  • 无论BRAF状态、既往BRAF/MEK抑制剂治疗及预后特征(乳酸脱氢酶升高、大肿瘤体积、脑转移),总生存HR均 favoring 帕博利珠单抗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Immune checkpoint inhibitors have led to unprecedented prolongation of overall survival (OS) for patients with advanced melanoma. Five-year follow-up of KEYNOTE-006 showed pembrolizumab prolonged survival versus ipilimumab. Efficacy results with 7-year follow-up are presented. At data cutoff (April 19, 2021), median follow-up was 85.3 months (range, 0.03-90.8 months). Median OS was 32.7 months for pembrolizumab versus 15.9 months for ipilimumab (hazard ratio [HR], 0.70; 95% CI, 0.58 to 0.83); 7-year OS was 37.8% and 25.3%, respectively. OS HRs favored pembrolizumab regardless of BRAF status or prior BRAF/MEK-inhibitor treatment and prognostic characteristics (elevated lactate dehydrogenase, large tumor size, and brain metastasis). Median modified progression-free survival (mPFS) was 9.4 months for pembrolizumab versus 3.8 months for ipilimumab; 7-year mPFS was 23.8% and 13.3%, respectively. In patients who completed ≥94 weeks of pembrolizumab, the 5-year OS was 92.9% and the 5-year mPFS was 70.1%. The objective response rate with second-course pembrolizumab (n = 16) was 56% (95% CI, 30 to 80) and the 2-year mPFS was 62.5%. These findings confirm that pembrolizumab provides long-term survival benefit in advanced melanoma.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Robert C, Carlino MS, McNeil C, et al. Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma. J Clin Oncol. 2023. PMID: 37348035. doi:10.1200/JCO.22.01599

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。